Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEco Animal Regulatory News (EAH)

Share Price Information for Eco Animal (EAH)

Share Price is delayed by 15 minutes
Get Live Data
93.00    0.00 (0.00%)
Bid:
91.00
Ask:
95.00
Spread: 4.00 (4.396%)
Market Cap: £62.39m
EAH Live PriceLast checked at - London Stock Exchange

Intraday Eco Animal Share Chart

Board Changes

26 Jul 2021 07:00

RNS Number : 3680G
Eco Animal Health Group PLC
26 July 2021
 

 

ECO Animal Health Group plc

(''ECO" or "the Group")

(AIM: EAH)

 

Board Changes

 

 

 

CEO to retire in FY 2022-23

 

 

Marc Loomes, who joined ECO Animal Health Group plc in 2004, became Managing Director in 2005 and CEO in 2010, has informed the Board that he plans to retire on 31 December 2022. During his tenure, the Company has grown sales revenues over sevenfold from £14m to over £100m.

 

The Board has therefore commenced a formal process with a leading executive search consultancy to identify and appoint a successor to take over from Marc during the 2022-23 financial year.

 

Marc Loomes, CEO said:

"ECO has grown rapidly and undergone many changes particularly over the past five years. We are enjoying strong trading and have established a solid platform for the next stage of ECO's future growth with our vaccine development portfolio. I have thoroughly enjoyed my time at ECO and I am proud of what we have achieved. I believe that these timescales reflect the right time to hand over to a new CEO who will be most ably supported by a strong operational executive leadership team."

 

Andy Jones, Chairman of ECO Animal Health, commented:

 "We have begun our search for Marc's successor and are confident of a smooth transition as Marc has agreed to stay with us during the 2022-23 year, until a successor is in place and a full and successful handover has been completed. We are hugely grateful to Marc for his significant contribution and strong leadership he has provided over the last 17 years, and his total commitment to ensure a smooth succession process."

 

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR") as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

 

 

Contacts:

 

ECO Animal Health Group plc

Andy Jones (Chairman)

Marc Loomes (CEO)

 

020 8447 8899

 

IFC Advisory

Graham Herring

Zach Cohen

 

020 3934 6630

 

Singer Capital Markets (Nominated Adviser & Joint Broker)

Mark Taylor

Peter Steel

Iqra Amin

 

020 7496 3000

Peel Hunt LLP (Joint Broker)

James Steel

Dr Christopher Golden

020 7418 8900

 

 

 

About ECO Animal Health

ECO Animal Health Group plc ("ECO" or "the "GROUP") researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOASELFUIEFSELW
Date   Source Headline
4th Jun 20267:00 amRNSRenewal of revolving credit facility
14th Apr 20267:00 amRNSAppointment of Head of Business Development
31st Mar 20267:00 amRNSBoard Change
19th Mar 20267:00 amRNSFull Year Trading Update
11th Mar 20267:00 amRNSECOVAXXIN® MG favourable USDA safety assessment
11th Mar 20267:00 amRNSECOVAXXIN®?MG favourable USDA safety assessment
5th Mar 20264:19 pmRNSBlock Listing Return
26th Feb 20267:00 amRNSEU launch plans for ECOVAXXIN® MS
19th Jan 20261:50 pmRNSHolding(s) in Company
22nd Dec 20257:00 amRNSECOVAXXIN® MS EU marketing authorisation granted
22nd Dec 20257:00 amRNSECOVAXXIN® MS EU marketing authorisation granted
18th Dec 20257:00 amRNSExercise of Share Options by Director
9th Dec 20255:57 pmRNSHolding(s) in Company
4th Dec 20252:10 pmRNSDirector/PDMR Shareholding
1st Dec 20257:00 amRNSResults for the six months ended 30 September 2025
20th Nov 20259:47 amRNSReplacement: Notice of Results
20th Nov 20257:00 amRNSNotice of Results
10th Nov 20257:00 amRNSEMA Positive Opinion Received for ECOVAXXIN® MS
1st Oct 20257:00 amRNS-RHead of Global R&D
25th Sep 20253:15 pmRNSResult of AGM
25th Sep 20257:00 amRNSAGM Trading Update and Notice of Interim Results
1st Sep 20257:00 amRNSAppointment of Joint Broker
29th Aug 20257:00 amRNSShare Awards to Executive Directors
28th Aug 20257:48 amRNSPosting of Annual Report and Notice of AGM
21st Aug 202512:29 pmRNSResult of General Meeting
13th Aug 20257:00 amRNSBlock Listing Return
6th Aug 20255:09 pmRNSHolding(s) in Company
17th Jul 20257:00 amRNSHolding(s) in Company
15th Jul 20251:00 pmRNSDirector/PDMR Shareholding
14th Jul 20257:00 amRNSResults for the year ended 31 March 2025
8th Jul 20254:10 pmRNSNotice of General Meeting and Notice of Results
2nd May 20257:00 amRNSHolding(s) in Company
28th Apr 20257:00 amRNSDirector/PDMR Shareholding
24th Apr 20257:00 amRNSTrading Update
13th Mar 20257:00 amRNSR&D Day
3rd Mar 20257:00 amRNSSubmission of Marketing Authorisation Application
24th Feb 20254:08 pmRNSHolding(s) in Company
19th Feb 20257:00 amRNSDisposal of non-core assets
18th Feb 20257:00 amRNSBlock listing Interim Review
13th Feb 20257:00 amRNSNotice of R&D Day
31st Jan 20257:00 amRNSBoard Changes
20th Dec 20247:00 amRNSHolding(s) in Company
16th Dec 20247:00 amRNSHolding(s) in Company
2nd Dec 202412:30 pmRNSShare Purchase by Executive Director
28th Nov 20247:00 amRNSResults for the Six Months Ended 30 September 2024
28th Oct 202412:57 pmRNSShare Awards to Executive Directors
22nd Oct 202411:00 amRNSEBT Share Purchase
21st Oct 20247:00 amRNSEBT Share Purchase
14th Oct 202411:07 amRNSEBT Share Purchase
9th Oct 20247:00 amRNSIssue of Equity and TVR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.